MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
MRUS

MRUS

Merus N.V.

$90
0
 (0%)
Exchange:  NASDAQ
Market Cap:  6.826B
Shares Outstanding:  15.407M
Delayed data
Calculate MRUS Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Jan van de Winkel
Full Time Employees:  260
Address: 
Yalelaan 62
Utrecht
3584 CM
NL
Website:  https://www.merus.nl
Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202220232024
Revenue38,837.16539,807.19234,879.184
Gross Profit28,883.65929,306.25312,958.187
EBITDA-148,259.426-139,499.540-260,241.018
Operating Income-149,459.488-141,800.272-262,626.275
Net Income-122,522.076-140,343.746-207,854.187

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202220232024
Total Assets376,542455,494785,130
Total Liabilities129,48799,151134,766
Total Stockholders Equity247,055356,343647,927
Total Debt13,47412,1629,912
Cash and Cash Equivalents147,749205,046293,294

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202220232024
Operating Cash Flow-149,899-142,207-185,835
Capital Expenditure-7,639-3,982-1,667
Free Cash Flow-157,538-146,189-187,502
Net Income-131,194-154,939-215,326
Net Change in Cash-93,31056,59789,017

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)357,991.590Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)2,441,172.454Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,224,526.957Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-2,441,172.454Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-357,991.590Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-1,224,526.957Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)27,565.479Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)789,079.267Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)344,330.554Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)496,674.892Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,386,864.663Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,698,899.671Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)5.360Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)12.290Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.430Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
36.133M  ?P/S
 (TTM)
: 
128.91
?Net Income
 (TTM)
: 
-215326000  ?P/E
 (TTM)
: 
-19.52
?Enterprise Value
 (TTM)
: 
6.523B  ?EV/FCF
 (TTM)
: 
-20.52
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.51  ?ROIC
 (TTM)
: 
-0.49
?Net Debt
 (TTM)
: 
-527815000  ?Debt/Equity
 (TTM)
: 
0.02
?P/B
 (TTM)
: 
10.29  ?Current Ratio
 (TTM)
: 
7.97

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about MRUS valuation

Is Merus N.V. (MRUS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Merus N.V. (MRUS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is MRUS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MRUS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is MRUS’s P/E ratio?

You can see MRUS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for MRUS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is MRUS a good long-term investment?

Whether MRUS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

MRUS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0
MARKETSnap

Trading Metrics:

Open: 90   Previous Close: 90
Day Low: 90   Day High: 90
Year Low: 33.19   Year High: 97.14
Price Avg 50: 95.61   Price Avg 200: 68.01
Volume: 2.721M   Average Volume: 1.717M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read